Anti-IL-4/-13 based therapy in asthma

Expert Opinion on Emerging Drugs

Volumn 20, Issue 3, 2015, Pages 349-352

  Walsh, Garry M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

asthma; discriminatory biomarkers; IL 13; IL 4

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 5; ANTIASTHMATIC AGENT; BIOLOGICAL PRODUCT;

ASTHMA; BIOLOGICAL THERAPY; EDITORIAL; HUMAN; INFLAMMATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; RESPIRATORY TRACT INFLAMMATION; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL PRODUCTS; HUMANS; INFLAMMATION; INTERLEUKIN-13; INTERLEUKIN-4;

EID: 84940393746     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1050377     Document Type: Editorial

References (26)

1. Anderson GP. Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107-19
2. Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25: 552-63
3. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180: 817-22
4. Berger WE. New approaches to managing asthma: A US perspective. Ther Clin Risk Manag 2008; 4: 363-79
5. Shaw DE, Green RH, Bradding P. Asthma exacerbations: Prevention is better than cure. Ther Clin Risk Manag 2005; 1(4): 273-7
6. Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov 2012; 11: 958-72
7. Walsh GM. An update on emerging drugs for asthma. Expert Opinion Emerg Drugs 2012; 17(1): 37-42
8. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-60
9. Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004; 114: 1106-9
10. Saha SK, Berry MA, Parker D, et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121: 685-91
11. Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs 2010; 11: 1305-12
12. May R, Monk P, Cohen E, et al. Preclinical development of CAT-354, an IL-13-neutralising antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012; 166: 177-93
13. Piper E, Brightling C, Niven R Oh C, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2013; 4: 330-8
14. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-98
15. Jia G, Erickson RW, Choy DF Mosesova S, Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroidrefractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-54
16. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol 2013; 132(3): 567-74
17. Diamant Z, Gauvreau GM, Cockcroft DW, et al. Inhaled allergen bronchoprovocation tests. J Allergy Clin Immunol 2013; 132: 1045-55
18. Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy 2014; 44: 38-46
19. Jiang H, Harris MB, Rothman P. IL-4/ IL-13 signalling beyond JAK/STAT. J Allergy Clin Immunol 2000; 105: 1063-70
20. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368(26): 2455-66
21. Wechsler ME, Inhibiting IL-4 and IL-13 in difficult-to-control asthma. N Engl J Med 2013; 368(26): 2511-13
22. Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013; 10(Suppl): S206-13
23. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99
24. Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371(2): 130-9
25. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-83
26. Aryan Z, Holgate ST, Radzioch D, Rezaei N. A new era of targeting the ancient gatekeepers of the immune system: Toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol 2014; 164(1): 46-63